The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. 

After discovering a new mechanism for DNA damage repair last year, Vanderbilt biochemists now provide direct evidence for how it works.

Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data.

Gautam (Jay) Bhave, MD, PhD, assistant professor of Medicine and Cell & Developmental Biology, is the recipient of the 2020 Grant W. Liddle Award for “exemplary leadership in the promotion of scientific research” at Vanderbilt University Medical Center.

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions.

Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.